Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by analysts at Scotiabank in a note issued to investors on Thursday. They currently have a $17.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $32.00. Scotiabank’s price target suggests a potential downside of 5.56% from the stock’s previous close.

A number of other research firms also recently weighed in on VRX. Mizuho upgraded shares of Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and set a $25.00 price target on the stock in a report on Thursday, August 11th. Rodman & Renshaw reiterated a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. TD Securities reiterated a “hold” rating and issued a $38.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Wells Fargo & Co. reiterated an “underperform” rating and issued a $19.50 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, August 10th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $33.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, November 3rd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 18.00 on Thursday. The firm’s 50 day moving average price is $22.04 and its 200-day moving average price is $25.21. Valeant Pharmaceuticals International has a 52 week low of $13.77 and a 52 week high of $119.87. The stock’s market cap is $6.26 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.74 EPS. Analysts expect that Valeant Pharmaceuticals International will post $5.63 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Kistler Tiffany Companies LLC raised its position in shares of Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the last quarter. US Bancorp DE raised its position in shares of Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the last quarter. Sapphire Star Partners LP raised its position in shares of Valeant Pharmaceuticals International by 100.0% in the first quarter. Sapphire Star Partners LP now owns 6,000 shares of the specialty pharmaceutical company’s stock worth $608,000 after buying an additional 3,000 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the last quarter. Finally, Boothbay Fund Management LLC raised its position in shares of Valeant Pharmaceuticals International by 275.4% in the first quarter. Boothbay Fund Management LLC now owns 7,632 shares of the specialty pharmaceutical company’s stock worth $201,000 after buying an additional 5,599 shares during the last quarter. Institutional investors own 64.39% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.